Payment overview · 2025
General Payments
$64.22
3 reported records · 2 companies
Healthcare provider profile · identity verified
Winny Ou, MD
Allopathic & Osteopathic Physicians|Family Medicine · SOUTH EASTON, MA · NPI 1023003274
Verified facts
What the public records show
CMS Open Payments records show Winny Ou, MD received $64.22 in general payments during 2025 across 3 reported records.
Abbott Laboratories accounted for 69.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $44.30 | 69.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.92 | 31.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $64.22 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $44.30 | 2 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $19.92 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 593 | 170 |
| Lisinopril | Lisinopril | 456 | 122 |
| Levothyroxine Sodium | Levothyroxine Sodium | 319 | 60 |
| Omeprazole | Omeprazole | 284 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 221 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 165 | 48 |
| Simvastatin | Simvastatin | 161 | 41 |
| Lorazepam | Lorazepam | 130 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 118 | 30 |
| Gabapentin | Gabapentin | 115 | 29 |
| Losartan Potassium | Losartan Potassium | 115 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 105 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 104 | 36 |
| Prednisone | Prednisone | 97 | 45 |
| Sertraline Hcl | Sertraline Hcl | 96 | 25 |
| Alendronate Sodium | Alendronate Sodium | 93 | 27 |
| Ibuprofen | Ibuprofen | 93 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 83 | 23 |
| Ozempic | Semaglutide | 82 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 80 | 33 |
| Allopurinol | Allopurinol | 74 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 73 | 17 |
| Metformin Hcl Er | Metformin Hcl | 70 | 22 |
| Clonazepam | Clonazepam | 65 | suppressed |
| Eliquis | Apixaban | 62 | 18 |
| Metformin Hcl | Metformin Hcl | 60 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 60 | 18 |
| Trazodone Hcl | Trazodone Hcl | 59 | 19 |
| Oxycodone Hcl | Oxycodone Hcl | 58 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 57 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 56 | 17 |
| Furosemide | Furosemide | 54 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 54 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 52 | suppressed |
| Atenolol | Atenolol | 51 | 13 |
| Carvedilol | Carvedilol | 49 | 16 |
| Cephalexin | Cephalexin | 49 | 39 |
| Mirtazapine | Mirtazapine | 49 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 47 | 15 |
| Montelukast Sodium | Montelukast Sodium | 43 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 37 | suppressed |
| Potassium Chloride | Potassium Chloride | 37 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 31 | 14 |
| Fluconazole | Fluconazole | 30 | 17 |
| Spironolactone | Spironolactone | 30 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 29 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 19 |
| Nystatin | Nystatin | 29 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 23 |
| Meloxicam | Meloxicam | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 13 |
| Valsartan | Valsartan | 28 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 27 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 27 | suppressed |
| Glipizide | Glipizide | 27 | 12 |
| Valacyclovir | Valacyclovir Hcl | 27 | 17 |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Hydrocortisone | Hydrocortisone | 25 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 22 |
| Tramadol Hcl | Tramadol Hcl | 24 | suppressed |
| Carisoprodol | Carisoprodol | 23 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 21 | 16 |
| Glipizide Er | Glipizide | 21 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 15 |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Famotidine | Famotidine | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $64.22 · 3 records | Abbott Laboratories | FREESTYLE LIBRE 3, SYNTHROID, UBRELVY | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Synthroid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error